You are here: Industry Insights > NICE

News List

RCGP responds to new NICE Quality Standard in physical activity pharmatimes
June 11, 2019
The National institute for Health and Care Excellence (NICE) has released a new guidance encouraging employers to help their staff become active in a fight against obesity.
NICE recommendation for MSD’s Prevymis after re-evaluation pharmatimes
June 03, 2019
Document, recommending MSD’s Prevymis (letermovir) for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) within the NHS.
Final NICE guidance issued for Akcea’s Tegsedi pharmatimes
May 28, 2019
Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage drug, Tegsedi (inotersen).
NICE recommends Revlimid as multiple myeloma alternative pharmatimes
May 20, 2019
The National Institute of Health and Care Excellence (NICE) has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight blood cancer.
Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
NICE recommends Sprinraza for 5q spinal muscular atrophy pharmatimes
May 15, 2019
The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS).
NICE backs use of Ocrevus in primary progressive multiple sclerosis after Roche reaches pricing deal with NHS firstwordpharma
May 10, 2019
The National Institute for Health and Care Excellence issued final draft guidance Thursday recommending NHS reimbursement of Roche's Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults.
NICE approves 3 drugs for treating plaque psoriasis in children europeanpharmaceuticalreview
May 07, 2019
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children…
NICE recommends Akcea's Tegsedi for rare, life-threatening progressive disease pharmafile
April 23, 2019
NICE recommends Akcea's Tegsedi for rare, life-threatening progressive disease

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page